Skip to main content Skip to section navigation Skip to footer
Stock Information
chevron_left Back to CastleBiosciences.com
Castle Biosciences, Inc. IR Home
  • Overview
  • News & Events keyboard_arrow_down
    • Press Releases
    • IR Events
    • Presentations
    • In The Media
    • Annual Meeting
    • Email Alerts
  • Company Info keyboard_arrow_down
    • Company Profile
    • Executive Team
    • Annual Reports & Proxy
    • Contacts
    • FAQ
  • Financial Info keyboard_arrow_down
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data keyboard_arrow_down
    • Quote & Chart
    • Historical Data
    • Analyst Coverage
  • SEC Filings keyboard_arrow_down
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance keyboard_arrow_down
    • Governance Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Corporate Responsibility
  • Resources keyboard_arrow_down
    • Scientific Evidence
  • Stock Information
  • chevron_leftBack to CastleBiosciences.com

In The Media

News & Events

  • Press Releases
  • IR Events
  • Presentations
  • In The Media
  • Annual Meeting
  • Email Alerts
Aug 9, 2021
EatingWell: I'm a Skin Cancer Survivor & This Is My Best Advice on How to Protect Your Skin
Jul 27, 2021
Targeted Oncology: Risk Information Can Influence Clinical Decision-Making in Melanoma
Jun 20, 2021
Houston Chronicle: 2021 CHRON100, Market Value, Market Return and Revenue Growth
Jun 9, 2021
genomeweb: Castle Biosciences Receives NYS DOH Approval for Skin Cancer Diagnostic
May 21, 2021
clpMagazine: Castle Biosciences to Acquire Myriad MyPath Laboratory
May 11, 2021
genomeweb: Castle Biosciences to Expand Range of Dermatology Diagnostics Beyond Cancer
May 11, 2021
360Dx: Castle Biosciences to Expand Range of Dermatology Diagnostics Beyond Cancer
May 6, 2021
2021 MedTech Breakthrough Awards: Best New Technology Solution – Oncology, for DecisionDx®-SCC and DecisionDx® DiffDx™
Apr 27, 2021
BioWorld MedTech: Castle fortifies position in skin cancer detection with $32.5M Myriad Mypath acquisition
Apr 13, 2021
Practical Dermatology: DecisionDx-Melanoma Accurately Predicts Patient Outcomes in Cutaneous Melanoma
rss_feed RSS
  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 17
  • Page 18
  • Page 19
  • Page 20
  • Page 21
  • Page 22
  • Page 23
  • Page 24
  • Page 25
  • Page 26
  • Next Pagearrow_forward
  • emailEmail Alerts
  • location_cityCompany Profile
  • contact_pageContacts
  • rss_feedRSS News Feed
©2026 Castle Biosciences, Inc. All Rights Reserved.
  • Privacy Policy
  • Disclaimer
  • Sitemap
  • Accessibility Statement

Market Data copyright © 2026 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.